Ibogaine research archive

Cardiac Safety Dossier

A focused evidence archive on ibogaine and noribogaine, centered on electrophysiology, QT/QTc findings, reported adverse events, interaction risks, and the limits of the current record.

QT / QTc
Case reports
PK–PD uncertainty
Protocol safeguards

Close study detail accompanying the cardiac safety evidence dossier

01 / Signal

QTc is the central measurable concern.

Ibogaine and noribogaine are discussed in the cardiac-safety literature because of concern about delayed ventricular repolarization, generally assessed with the QT interval corrected for heart rate. A prolonged QT interval is clinically important because it can create conditions associated with torsades de pointes, a distinctive polymorphic ventricular tachycardia described in standard descriptions of torsades de pointes.

The evidence should be read as a pattern rather than a single number. Useful reporting includes the mean QTc change from baseline, its variability, the number and proportion of participants crossing clinically relevant QTc thresholds, the largest observed value, and when each measurement was obtained relative to dosing. Without those standardized elements, apparently reassuring averages can conceal a small number of pronounced responses.

“A QTc summary is most informative when it shows both the center and the edge of the distribution.”

Direct comparison between studies remains difficult. Correction approaches such as Bazett and Fridericia can yield different values, particularly when heart rate changes. Small samples, variable prior substance exposure, and uneven ECG schedules further limit confident estimates of dose response. The broader evidence archive’s organized research context is useful for keeping such limitations visible rather than treating a QTc value as a stand-alone verdict.

02 / Reports

Case reports matter, but they do not yield a simple rate.

Published reports have linked ibogaine exposure with marked QT prolongation, torsades de pointes, ventricular arrhythmia, and sudden death. These reports warrant careful attention because their clinical consequences can be severe. At the same time, a case report cannot establish incidence: exposure totals, product identity, dosing conditions, co-exposures, baseline health, and post-event investigation vary substantially.

Many reported cases involve possible overlapping contributors, including other substances, medications with QT-prolonging potential, vomiting or poor intake, and low potassium or magnesium. That does not remove concern about ibogaine; it clarifies why causal assessment must account for a multi-factor risk environment. The U.S. Food and Drug Administration’s safety communication on abnormal rhythms and electrolyte abnormalities illustrates the wider clinical principle that QT-related risk can rise when multiple vulnerabilities coincide.

For a responsible dossier, each report should distinguish documented facts from inference: ECG findings, timing, toxicology where available, known medicines, electrolyte results, resuscitation details, and alternative explanations. The site’s regulatory and ethics guide adds context on why safety evidence needs transparent reporting even when evidence is incomplete.

Research material used to frame reported cardiac safety evidence

03 / Context

Risk is shaped by exposure, metabolism, and co-factors.

Co-administered QT-prolonging drugs

Combining agents that affect repolarization can complicate attribution and may increase risk. A meaningful medication review needs to include prescribed drugs, non-prescribed substances, and recently discontinued agents whose effects may persist.

Electrolyte disturbance

Low potassium or magnesium, dehydration, vomiting, and poor intake are relevant because they can reduce physiologic reserve against arrhythmia. Baseline and repeat laboratory values matter more than assumptions based on appearance or history alone.

Noribogaine and delayed exposure

Ibogaine is metabolized to noribogaine, and the metabolite’s activity and persistence make a narrow, immediate post-dose window an incomplete safety frame. Better studies need concentration and ECG measurements across the relevant time course.

Pharmacokinetic–pharmacodynamic uncertainty

Individual exposure can vary with metabolism, liver function, product composition, dose, and co-medications. Existing data do not settle how circulating ibogaine or noribogaine concentrations map onto an individual QTc trajectory.

Mechanistic evidence is relevant, but it should not be mistaken for a complete clinical prediction. In nonclinical cardiac safety assessment, regulators expect structured evaluation of a medicine’s potential to delay repolarization. The ICH S7B guideline on nonclinical evaluation of delayed ventricular repolarization provides a recognized framework for interpreting this type of preclinical question.

For people looking for broader context on how claims about ibogaine are organized and qualified, the independent ibogaine treatment and depression evidence context is a separate resource; it does not resolve the cardiac uncertainties described here.

04 / Safeguards

Research protocols make risk controls explicit.

Monitoring is a method of observing risk, not a guarantee against it.

Published and proposed research procedures commonly emphasize eligibility screening, medication reconciliation, baseline cardiac assessment, electrolyte evaluation, serial ECGs, and escalation pathways for concerning findings. The exact approach should be specified rather than implied.

State which QTc correction method and thresholds are used.
Report ECG timing alongside dosing and measured exposure where available.
Prespecify how medication interactions and abnormal electrolytes are handled.
Document adverse-event adjudication and follow-up duration.

The responsible conclusion is caution paired with better measurement.

The present record supports sustained attention to cardiac risk, especially QT/QTc prolongation, arrhythmia reports, interaction burden, and the possibility of delayed effects related to noribogaine. It does not justify compressing heterogeneous studies and case reports into a simple safety claim.

Questions about evidence standards, access, and scope can be found in the site’s statement of independent purpose. This dossier is informational only and does not endorse a treatment, screening decision, or individual course of action.

Continue to the evidence primer